KalVista Pharmaceuticals, Inc.
KALV
$27.00
$0.010.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -34.64% | 337.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -31.81% | 337.66% | |||
| Cost of Revenue | 26.73% | -7.46% | |||
| Gross Profit | -46.83% | 10,111.13% | |||
| SG&A Expenses | -19.22% | 29.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.48% | 21.59% | |||
| Operating Income | -84.34% | 72.39% | |||
| Income Before Tax | -88.34% | 73.65% | |||
| Income Tax Expenses | -- | -429.09% | |||
| Earnings from Continuing Operations | -337.21% | 89.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -337.21% | 89.14% | |||
| EBIT | -84.34% | 72.39% | |||
| EBITDA | -90.33% | 73.49% | |||
| EPS Basic | -342.24% | 89.40% | |||
| Normalized Basic EPS | -98.38% | 75.71% | |||
| EPS Diluted | -342.24% | 89.40% | |||
| Normalized Diluted EPS | -98.38% | 75.71% | |||
| Average Basic Shares Outstanding | -1.09% | 2.42% | |||
| Average Diluted Shares Outstanding | -1.09% | 2.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||